PharmTech Drug Digest 11.20
News|Articles|October 8, 2013

Hovione Passes FDA Inspection

Hovione's plant in Portugal has successfully passed its twelfth FDA inspection in 18 months.

Hovione's plant in Loures, Portugal has passed a GMP and postmarket approval inspection by FDA. The inspection lasted five days as initially planned, and began on Sept. 23, 2013 was concluded on Sept. 27, 2013. At the closing meeting, the inspector was satisfied the company's GMP system, and the inspection was sucessful.

Hovione’s five plants were the object of 12 inspections in the last 18 months. These inspections were performed by health authorities, including five by FDA, three by the Portuguese Health Authority, one by the Irish Medicines Board, one by Korean health authorities, and two by China’s health authority.

Source: Hovione


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.